Viruses (Oct 2021)
The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City
- Alberto Cedro-Tanda,
- Laura Gómez-Romero,
- Nicolás Alcaraz,
- Guillermo de Anda-Jauregui,
- Fernando Peñaloza,
- Bernardo Moreno,
- Marco A. Escobar-Arrazola,
- Oscar A. Ramirez-Vega,
- Paulina Munguia-Garza,
- Francisco Garcia-Cardenas,
- Mireya Cisneros-Villanueva,
- Jose L. Moreno-Camacho,
- Jorge Rodriguez-Gallegos,
- Marco A. Luna-Ruiz Esparza,
- Miguel A. Fernández Rojas,
- Alfredo Mendoza-Vargas,
- Juan Pablo Reyes-Grajeda,
- Abraham Campos-Romero,
- Ofelia Angulo,
- Rosaura Ruiz,
- Claudia Sheinbaum-Pardo,
- José Sifuentes-Osornio,
- David Kershenobich,
- Alfredo Hidalgo-Miranda,
- Luis A. Herrera
Affiliations
- Alberto Cedro-Tanda
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Laura Gómez-Romero
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Nicolás Alcaraz
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Guillermo de Anda-Jauregui
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Fernando Peñaloza
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Bernardo Moreno
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Marco A. Escobar-Arrazola
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico
- Oscar A. Ramirez-Vega
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico
- Paulina Munguia-Garza
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico
- Francisco Garcia-Cardenas
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Mireya Cisneros-Villanueva
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Jose L. Moreno-Camacho
- Clinical Laboratory Division, Salud Digna, Culiacan, Sinaloa 80000, Mexico
- Jorge Rodriguez-Gallegos
- Clinical Laboratory Division, Salud Digna, Culiacan, Sinaloa 80000, Mexico
- Marco A. Luna-Ruiz Esparza
- Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico
- Miguel A. Fernández Rojas
- Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico
- Alfredo Mendoza-Vargas
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Juan Pablo Reyes-Grajeda
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Abraham Campos-Romero
- Innovation and Research Department, Salud Digna, Culiacan, Sinaloa 80000, Mexico
- Ofelia Angulo
- Secretaría de Educación, Ciencia, Tecnología e Innovacion, Av Chapultepec 49, Colonia Centro, Cuauhtémoc, Mexico City 06010, Mexico
- Rosaura Ruiz
- Secretaría de Educación, Ciencia, Tecnología e Innovacion, Av Chapultepec 49, Colonia Centro, Cuauhtémoc, Mexico City 06010, Mexico
- Claudia Sheinbaum-Pardo
- Gobierno de la Ciudad de México, Antiguo Palacio del Ayuntamiento, Avenida Plaza de la Constitución 2, Colonia Centro, Mexico City 06010, Mexico
- José Sifuentes-Osornio
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico
- David Kershenobich
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico
- Alfredo Hidalgo-Miranda
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- Luis A. Herrera
- Instituto Nacional de Medicina Genómica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico
- DOI
- https://doi.org/10.3390/v13112182
- Journal volume & issue
-
Vol. 13,
no. 11
p. 2182
Abstract
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. We reported the effective reproduction number (Rt) of B.1.1.519 and presented evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519. The B.1.1.519 variant was predominant between November 2020 and May 2021, reaching 90% of all cases sequenced in February 2021. It is characterized by three amino acid changes in the spike protein: T478K, P681H, and T732A. Its Rt varies between 0.5 and 2.9. Its geographical origin remain to be investigated. Patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (p = 0.000296, 1.33–2.6 95% CI) and a 2.35-fold increase for hospitalization (p = 0.005, 1.32–4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.
Keywords
- SARS-CoV-2
- B.1.1.519 variant
- effective reproduction number
- phylogenetic analysis
- haplotype analysis
- clinical impact